Evolent Health Inc (EVH)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $554.22M
Last updated: Nov 17, 2026 at 11:05 AM ET
Evolent Health Inc (EVH) Valuation Multiples
Evolent Health (EVH) trades at 0.2x sales and 1.5x book value. Its P/S of 0.2x is below its 5-year median of 1.5x. Its forward P/E is 14.0x.
Current Multiples
Its free cash flow yield is 6.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 14.0x |
| Price to sales | 0.2x |
| Price to book | 1.5x |
| Price to FCF | 14.9x |
| EV/FCF | 37.3x |
| PEG | N/A |
| FCF yield | 6.7% |
Historical Medians
Against its 10-year medians, its P/S is 88.9% below 1.8x and its P/B is 6.3% below 1.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.2x | 1.5x | 1.8x |
| P/B | 1.5x | 2.7x | 1.6x |
Valuation History
Over the 4 of the 10 year ends shown that have a P/E, its P/E ranged from 17.0x in 2024 to 200.0x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $4.00 | 200.0x | 0.2x | 1.1x |
| 2024 | $11.25 | 17.0x | 0.5x | 1.3x |
| 2023 | $33.03 | 37.5x | 1.9x | 3.5x |
| 2022 | $28.08 | 30.9x | 1.9x | 3.3x |
| 2021 | $27.67 | N/A | 2.6x | 3.5x |
| 2020 | $16.03 | N/A | 1.5x | 2.2x |
| 2019 | $9.05 | N/A | 1.1x | 0.8x |
| 2018 | $19.95 | N/A | 2.5x | 1.4x |
| 2017 | $12.30 | N/A | 1.8x | 0.9x |
| 2016 | $14.80 | N/A | 2.7x | 1.1x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EVH
What is EVH's forward P/E ratio?
Evolent Health has a forward P/E ratio of 14.0x.
Is EVH stock overvalued?
GNG's valuation label for EVH is Undervalued.
What is EVH's price to sales ratio?
Evolent Health has a price to sales ratio of 0.2x.
EVH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors